Naveen Kumar Kushwaha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Naveen Kumar Kushwaha has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Prashant Gupta
Department of Surgical Oncology, Command Hospital Kolkata, Kolkata, India
6 shared publications - Laleng Mawia Darlong
Department of Thoracic Oncosurgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
5 shared publications - Nihanthy D. Sreenath
Department of Medical Oncology, Saroj Gupta Cancer Centre and Research Institute, Kolkata, West Bengal, India
3 shared publications - Manisha Aggarwal
Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
2 shared publications Neha Garg
Department of Thoracic Oncosurgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
2 shared publications- Niharika Mishra
Department of Pathology, Command Hospital Kolkata, Kolkata, India
2 shared publications
Latest Publications
- 2 December 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1)
Gastrointestinal Stromal Tumours: Epitome of Variability
- 2 December 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1)
Gastrointestinal Stromal Tumours: Epitome of Variability
- 4 November 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (7) , 1-13
Neo-Rib Technique of Chest Wall Reconstruction Following Oncological Resection: An Institutional Experience
- 4 November 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (7) , 1-13
Neo-Rib Technique of Chest Wall Reconstruction Following Oncological Resection: An Institutional Experience
- 12 September 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (6) , 1-8
Metachronous Pulmonary Metastases in Soft Tissue Sarcoma: Prognostic Factors and Survival Outcomes Following Metastasectomy
Pulmonary metastasectomy (PM) remains a key component in the management of soft tissue sarcoma (STS) patients with isolated lung metastases. However, data on long-term outcomes and prognostic factors in Indian cohorts remain limited. We retrospectively analyzed 21 patients with previously treated soft tissue sarcoma (STS) who developed metachronous pulmonary metastases and underwent pulmonary metastasectomy (PM) at a tertiary care centre between January 2014 and March 2025. Demographic, clinical, radiological, and pathological variables were assessed. Survival outcomes were analysed using Kaplan–Meier estimates, and prognostic factors were evaluated using both univariate and multivariate Cox regression analyses. The median overall survival (OS) following PM was 66 months (95% CI: 32–85 months), with an estimated 5-year OS of 38% (95% CI: 20%–56%). On univariate analysis, a significantly better disease-free interval post-PM was observed in patients undergoing a single video-assisted thoracoscopic surgery (VATS) (p = 0.006), with ≤ 5 pulmonary nodules (p = 0.037), and with nodules ≤ 2 cm in size (p = 0.009). Other variables, including age, primary tumour site, laterality of nodules, and chemotherapy, showed no significant association with survival. Multivariate analysis did not identify any independent predictors, likely due to the small sample size. Six patients (28.5%) underwent repeat metastasectomy for recurrence. A disease-free interval (DFI) ≥ 12 months was associated with improved OS, although the difference was not statistically significant (p = 0.166). PM offers favourable long-term survival in carefully selected STS patients with metachronous lung metastases. Prognostic indicators such as limited metastatic burden and smaller nodule size are associated with improved outcomes. Further multicentre prospective studies are warranted to validate these findings and refine patient selection criteria.
- 12 September 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (6) , 1-8
Metachronous Pulmonary Metastases in Soft Tissue Sarcoma: Prognostic Factors and Survival Outcomes Following Metastasectomy
Pulmonary metastasectomy (PM) remains a key component in the management of soft tissue sarcoma (STS) patients with isolated lung metastases. However, data on long-term outcomes and prognostic factors in Indian cohorts remain limited. We retrospectively analyzed 21 patients with previously treated soft tissue sarcoma (STS) who developed metachronous pulmonary metastases and underwent pulmonary metastasectomy (PM) at a tertiary care centre between January 2014 and March 2025. Demographic, clinical, radiological, and pathological variables were assessed. Survival outcomes were analysed using Kaplan–Meier estimates, and prognostic factors were evaluated using both univariate and multivariate Cox regression analyses. The median overall survival (OS) following PM was 66 months (95% CI: 32–85 months), with an estimated 5-year OS of 38% (95% CI: 20%–56%). On univariate analysis, a significantly better disease-free interval post-PM was observed in patients undergoing a single video-assisted thoracoscopic surgery (VATS) (p = 0.006), with ≤ 5 pulmonary nodules (p = 0.037), and with nodules ≤ 2 cm in size (p = 0.009). Other variables, including age, primary tumour site, laterality of nodules, and chemotherapy, showed no significant association with survival. Multivariate analysis did not identify any independent predictors, likely due to the small sample size. Six patients (28.5%) underwent repeat metastasectomy for recurrence. A disease-free interval (DFI) ≥ 12 months was associated with improved OS, although the difference was not statistically significant (p = 0.166). PM offers favourable long-term survival in carefully selected STS patients with metachronous lung metastases. Prognostic indicators such as limited metastatic burden and smaller nodule size are associated with improved outcomes. Further multicentre prospective studies are warranted to validate these findings and refine patient selection criteria.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (9) , 1218-1220
From Present to Future: The Shifting Paradigm of Advanced Hepatocellular Carcinoma
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (9) , 1218-1220
From Present to Future: The Shifting Paradigm of Advanced Hepatocellular Carcinoma
- 16 June 2025
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 41 (9) , 1262-1267
Buttonhole LASER pulmonary metastasectomy: an innovative parenchyma preserving technique
With advances in systemic anticancer therapies, pulmonary metastasectomy is being increasingly employed for local disease control while aiming to preserve lung parenchyma, anatomy, and function with complete (R0) resection. We introduce an innovative neodymium-doped yttrium aluminum garnet (Nd-YAG) light amplification by stimulated emission of radiation (LASER) approach for peripherally located, deep-seated, and fissural lesions, utilizing the lung’s natural tongue-like configuration at the edges. This method involves cylindrical excision around the nodule, creating a buttonhole from one surface to the other. This approach minimizes parenchymal loss and maintains anatomical integrity, ensuring adequate lung expansion. We refer to this as the Nd-YAG LASER buttonhole pulmonary metastasectomy. Ten patients who underwent Nd-YAG LASER buttonhole pulmonary metastasectomy for synchronous and metachronous lesions at a tertiary oncology center in India between October 2023 and December 2024 were identified from a prospective database. Data was collected retrospectively from patient records from PARAS software, operative recordings, and clinical imaging systems. Between October 2023 and December 2024, 62 patients underwent Nd-YAG LASER–assisted pulmonary metastasectomy, with 10 patients undergoing buttonhole metastasectomy based on specific criteria. The procedure demonstrated efficacy in managing multiple and bilateral metastases, with 83.3% of bilateral cases completed in a single stage. In this cohort of 10 cases, 43 metastatic lesions were resected, out of which 27 were excised using LASER, including 14 via the buttonhole approach. This technique achieved precise excision with minimal parenchymal loss, maintaining a mean clear margin of 2.78 mm. Postoperative recovery was uneventful, and all patients remained disease-free at follow-up. For deep-seated peripheral lung lesions in the outer third of the lung, especially near the mediastinal pleura, diaphragm, or fissures, Nd-YAG LASER–assisted buttonhole pulmonary metastasectomy serves as a safe and effective alternative to LASER coring, stapled wide wedge resection, or segmentectomy. This technique enhances lung parenchymal preservation while allowing for potential future redo metastasectomies.
- 16 June 2025
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 41 (9) , 1262-1267
Buttonhole LASER pulmonary metastasectomy: an innovative parenchyma preserving technique
With advances in systemic anticancer therapies, pulmonary metastasectomy is being increasingly employed for local disease control while aiming to preserve lung parenchyma, anatomy, and function with complete (R0) resection. We introduce an innovative neodymium-doped yttrium aluminum garnet (Nd-YAG) light amplification by stimulated emission of radiation (LASER) approach for peripherally located, deep-seated, and fissural lesions, utilizing the lung’s natural tongue-like configuration at the edges. This method involves cylindrical excision around the nodule, creating a buttonhole from one surface to the other. This approach minimizes parenchymal loss and maintains anatomical integrity, ensuring adequate lung expansion. We refer to this as the Nd-YAG LASER buttonhole pulmonary metastasectomy. Ten patients who underwent Nd-YAG LASER buttonhole pulmonary metastasectomy for synchronous and metachronous lesions at a tertiary oncology center in India between October 2023 and December 2024 were identified from a prospective database. Data was collected retrospectively from patient records from PARAS software, operative recordings, and clinical imaging systems. Between October 2023 and December 2024, 62 patients underwent Nd-YAG LASER–assisted pulmonary metastasectomy, with 10 patients undergoing buttonhole metastasectomy based on specific criteria. The procedure demonstrated efficacy in managing multiple and bilateral metastases, with 83.3% of bilateral cases completed in a single stage. In this cohort of 10 cases, 43 metastatic lesions were resected, out of which 27 were excised using LASER, including 14 via the buttonhole approach. This technique achieved precise excision with minimal parenchymal loss, maintaining a mean clear margin of 2.78 mm. Postoperative recovery was uneventful, and all patients remained disease-free at follow-up. For deep-seated peripheral lung lesions in the outer third of the lung, especially near the mediastinal pleura, diaphragm, or fissures, Nd-YAG LASER–assisted buttonhole pulmonary metastasectomy serves as a safe and effective alternative to LASER coring, stapled wide wedge resection, or segmentectomy. This technique enhances lung parenchymal preservation while allowing for potential future redo metastasectomies.
- 31 May 2025
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 41 (9) , 1207-1211
Pleomorphic carcinoma of the lung with paraneoplastic fever as presentation
Pulmonary pleomorphic carcinoma (PPC) is a rare, highly aggressive variant of non-small cell lung cancer (NSCLC), comprising 0.1–0.4% of all pulmonary malignancies. While lung cancers typically present with symptoms like cough and hemoptysis, paraneoplastic syndromes are observed in about 10% of cases. Paraneoplastic fever as an initial manifestation is extremely rare. We present a rare case of PPC with neoplastic fever, emphasizing the importance of paraneoplastic syndromes during the evaluation of lung cancer. Surgical resection successfully alleviates neoplastic fever, highlighting the need to recognize paraneoplastic fever as a diagnostic challenge and consider it as a differential in cases of unexplained fever for prompt intervention.
- 31 May 2025
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 41 (9) , 1207-1211
Pleomorphic carcinoma of the lung with paraneoplastic fever as presentation
Pulmonary pleomorphic carcinoma (PPC) is a rare, highly aggressive variant of non-small cell lung cancer (NSCLC), comprising 0.1–0.4% of all pulmonary malignancies. While lung cancers typically present with symptoms like cough and hemoptysis, paraneoplastic syndromes are observed in about 10% of cases. Paraneoplastic fever as an initial manifestation is extremely rare. We present a rare case of PPC with neoplastic fever, emphasizing the importance of paraneoplastic syndromes during the evaluation of lung cancer. Surgical resection successfully alleviates neoplastic fever, highlighting the need to recognize paraneoplastic fever as a diagnostic challenge and consider it as a differential in cases of unexplained fever for prompt intervention.
- 19 May 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (2) , 361-367
Is Pneumonectomy Obsolete? Our Experience in the Current Clinical Landscape
Although the role of pneumonectomy has declined with advances in lung-sparing techniques and multimodal therapies, it remains essential in select cases. High morbidity and mortality remain concerns, but careful patient selection and perioperative optimization have improved outcomes. This study evaluates the relevance of pneumonectomy in the current clinical setting. A retrospective analysis was conducted of all pneumonectomy cases at a tertiary cancer centre in India from January 2015 to March 2024. Demographics, clinic-pathological characteristics, postoperative outcomes, and survival data were analyzed. Among 412 patients who underwent major lung resections, 19 (4.6%) required pneumonectomy. The mean age was 51.9 years (range 27–76); 74% were male, and 52% had a history of smoking. Left-sided pneumonectomy was more frequent (68.4%). Lung cancer was the most common indication (78.9%), followed by carcinoid tumours and inflammatory conditions (10.5% each). Postoperative complications occurred in five patients (26.3%). Two patients experienced early complications—atrial fibrillation and subcutaneous emphysema—while three developed bronchopleural or esophagopleural fistula in case of pleural windows, all requiring surgery. In-hospital mortality was 10.5% (two patients). The median follow-up was 13 months. Among cancer patients, median overall survival was longer for carcinoma than sarcoma (29 vs. 2 months), and for early- vs. locally advanced stage disease, though not statistically significant. The decline in pneumonectomy rates underscores advances in lung-sparing surgical techniques and alternative treatment modalities. Nevertheless, in the Indian context, where locally advanced lung cancer and extensive inflammatory lung damage are prevalent, pneumonectomy retains a significant role. With meticulous perioperative management, acceptable postoperative outcomes can still be consistently achieved.
- 19 May 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (2) , 361-367
Is Pneumonectomy Obsolete? Our Experience in the Current Clinical Landscape
Although the role of pneumonectomy has declined with advances in lung-sparing techniques and multimodal therapies, it remains essential in select cases. High morbidity and mortality remain concerns, but careful patient selection and perioperative optimization have improved outcomes. This study evaluates the relevance of pneumonectomy in the current clinical setting. A retrospective analysis was conducted of all pneumonectomy cases at a tertiary cancer centre in India from January 2015 to March 2024. Demographics, clinic-pathological characteristics, postoperative outcomes, and survival data were analyzed. Among 412 patients who underwent major lung resections, 19 (4.6%) required pneumonectomy. The mean age was 51.9 years (range 27–76); 74% were male, and 52% had a history of smoking. Left-sided pneumonectomy was more frequent (68.4%). Lung cancer was the most common indication (78.9%), followed by carcinoid tumours and inflammatory conditions (10.5% each). Postoperative complications occurred in five patients (26.3%). Two patients experienced early complications—atrial fibrillation and subcutaneous emphysema—while three developed bronchopleural or esophagopleural fistula in case of pleural windows, all requiring surgery. In-hospital mortality was 10.5% (two patients). The median follow-up was 13 months. Among cancer patients, median overall survival was longer for carcinoma than sarcoma (29 vs. 2 months), and for early- vs. locally advanced stage disease, though not statistically significant. The decline in pneumonectomy rates underscores advances in lung-sparing surgical techniques and alternative treatment modalities. Nevertheless, in the Indian context, where locally advanced lung cancer and extensive inflammatory lung damage are prevalent, pneumonectomy retains a significant role. With meticulous perioperative management, acceptable postoperative outcomes can still be consistently achieved.
- Open Access
- 1 May 2025
- Published by Elsevier in Medical Reports
- Vol. 12
Eosinophilic cholangitis: A benign condition masquerading as biliary malignancy
- 1 May 2025
- Published by Elsevier in Medical Reports
- Vol. 12
Open AccessEosinophilic cholangitis: A benign condition masquerading as biliary malignancy
- Open Access
- 20 February 2025
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
Optimizing Oncological Care in Patients with End-Stage Chronic Kidney Disease on Dialysis: Indian Scenario
Background In India, around 55,000 patients are on dialysis, with a 10–20% annual increase. With the growing dialysis population in India, cancer risk among end-stage renal disease (ESRD) patients is increasing. Managing chemotherapy in these patients is challenging due to limited data and guidelines, leading to treatment uncertainty. Objectives This study provides real-world data from India on the clinical management and outcomes of cancer patients with ESRD undergoing dialysis while receiving chemotherapy. Material and Methods This prospective study analyzed data from five cancer patients with end-stage renal disease (ESRD) on hemodialysis prior to diagnosis of cancer treated at a tertiary oncology center in India. We analyzed the demographic details, cancer staging, treatment regimens, and dosage adjustments. Treatment modifications due to renal dysfunction, toxicities, and patient outcomes were also reviewed over a 12-month follow-up. Results The cohort consisted of 80% (4/5 pts) females, with a median age of 57.8 years. Hypertensive and diabetic nephropathy were the leading causes of ESRD. Cancers included breast (3/5 pts), lung (1/5 pts), and ovarian (1/5 pts), with varying stages of diagnosis. 80% (4/5) of patients required tailored drug management. The Ovarian cancer patient experienced severe hypersensitivity to carboplatin, which was managed conservatively. No grade 3/4 immune-related adverse events occurred, and all patients were alive and disease-free at the one-year follow-up. Conclusion Carefully tailored treatment strategies and a coordinated multidisciplinary approach allowed positive outcomes for cancer patients on dialysis, emphasizing the need for personalized approaches. These findings highlight the importance of refining treatment protocols for this complex group.
- 20 February 2025
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
Open AccessOptimizing Oncological Care in Patients with End-Stage Chronic Kidney Disease on Dialysis: Indian Scenario
Background In India, around 55,000 patients are on dialysis, with a 10–20% annual increase. With the growing dialysis population in India, cancer risk among end-stage renal disease (ESRD) patients is increasing. Managing chemotherapy in these patients is challenging due to limited data and guidelines, leading to treatment uncertainty. Objectives This study provides real-world data from India on the clinical management and outcomes of cancer patients with ESRD undergoing dialysis while receiving chemotherapy. Material and Methods This prospective study analyzed data from five cancer patients with end-stage renal disease (ESRD) on hemodialysis prior to diagnosis of cancer treated at a tertiary oncology center in India. We analyzed the demographic details, cancer staging, treatment regimens, and dosage adjustments. Treatment modifications due to renal dysfunction, toxicities, and patient outcomes were also reviewed over a 12-month follow-up. Results The cohort consisted of 80% (4/5 pts) females, with a median age of 57.8 years. Hypertensive and diabetic nephropathy were the leading causes of ESRD. Cancers included breast (3/5 pts), lung (1/5 pts), and ovarian (1/5 pts), with varying stages of diagnosis. 80% (4/5) of patients required tailored drug management. The Ovarian cancer patient experienced severe hypersensitivity to carboplatin, which was managed conservatively. No grade 3/4 immune-related adverse events occurred, and all patients were alive and disease-free at the one-year follow-up. Conclusion Carefully tailored treatment strategies and a coordinated multidisciplinary approach allowed positive outcomes for cancer patients on dialysis, emphasizing the need for personalized approaches. These findings highlight the importance of refining treatment protocols for this complex group.
- 4 December 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (12) , e259115
Phenotypic plasticity in parotid tumours: insights from a surgical oncologist’s perspective
Phenotypic plasticity refers to the ability of tumour cells to undergo molecular and phenotypic changes in response to microenvironmental stresses, genetic and epigenetic alterations, or treatment-induced selective pressures, thereby promoting tumour progression. This case report discusses a man in his 70s with pleomorphic adenoma of the parotid, where phenotypic plasticity led to the development of pleomorphic liposarcoma in the parotid through transdifferentiation. Sarcomas can arise in the parotid from pre-existing pleomorphic adenomas or de novo, with only eight reported cases of primary parotid liposarcoma. The less studied pathway is the adenoma-carcinoma-sarcoma progression in pleomorphic adenoma of the parotid. This case report and literature review aim to investigate this evolutionary process and its implications for treatment planning and management from a surgical oncologist’s perspective.
- 4 December 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (12) , e259115
Phenotypic plasticity in parotid tumours: insights from a surgical oncologist’s perspective
Phenotypic plasticity refers to the ability of tumour cells to undergo molecular and phenotypic changes in response to microenvironmental stresses, genetic and epigenetic alterations, or treatment-induced selective pressures, thereby promoting tumour progression. This case report discusses a man in his 70s with pleomorphic adenoma of the parotid, where phenotypic plasticity led to the development of pleomorphic liposarcoma in the parotid through transdifferentiation. Sarcomas can arise in the parotid from pre-existing pleomorphic adenomas or de novo, with only eight reported cases of primary parotid liposarcoma. The less studied pathway is the adenoma-carcinoma-sarcoma progression in pleomorphic adenoma of the parotid. This case report and literature review aim to investigate this evolutionary process and its implications for treatment planning and management from a surgical oncologist’s perspective.